Sheila Bonilla-Tandoc, MD
Allergy & Immunology · Los Angeles, CANPI 1457387805
Payments from drug & device makers
Across 468 payments — averaging $70.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$20K
- Regeneron Healthcare Solutions, Inc.$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- AstraZeneca$2K
- Sanofi$1K
- Biocryst Pharmaceuticals, Inc.$1K
- plus $4K from 30 others
What the payments were for
- Consulting fees$4,44018%
- Speaking & faculty fees$10,40041%
- Food & beverage$10,24440%
- Education$2641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 101 | $19,699 |
| Regeneron Healthcare Solutions, Inc. | 41 | $2,786 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $2,087 |
| AstraZeneca | 56 | $1,839 |
| Sanofi | 62 | $1,225 |
| Biocryst Pharmaceuticals, Inc. | 1 | $1,125 |
| Biocryst US Sales Co., LLC | 43 | $626 |
| Novartis | 19 | $478 |
| Incyte Corporation | 14 | $298 |
| Pfizer | 9 | $245 |
| AbbVie(2 entities) | 5 | $217 |
| Ionis Pharmaceuticals, Inc. | 2 | $204 |
| LEO Pharma Inc. | 9 | $196 |
| CSL Behring | 9 | $193 |
| Sanofi-aventis U.S. LLC | 2 | $192 |
| Grifols USA, LLC | 5 | $163 |
| Octapharma USA, Inc. | 5 | $141 |
| Pharming Healthcare, Inc. | 6 | $135 |
| Amgen | 7 | $135 |
| Optinose US, Inc. | 6 | $127 |
| Cycle Pharmaceuticals Inc | 1 | $100 |
| Alk-abello, Inc | 4 | $95 |
| Shire North American Group Inc | 3 | $95 |
| Bio Products Laboratory USA, Inc. | 4 | $86 |
| Genentech USA, Inc. | 5 | $85 |
| Boehringer Ingelheim | 3 | $68 |
| Blueprint Medicines Corporation | 2 | $66 |
| Kaleo, Inc. | 3 | $61 |
| Teva Pharmaceuticals USA, Inc. | 3 | $58 |
| Phadia US Inc. | 2 | $36 |
| Galderma Laboratories, L.p. | 1 | $27 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| Organon | 1 | $23 |
| Kedrion Biopharma, Inc. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Verona Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,991 in reported general payments places this provider in the 80th percentile of 426 allergy & immunology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 43 | $240,250 |
| CuvitruImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $140,777 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 136 | $131,455 |
| FasenraBenralizumab | 11 | $55,771 |
| Breo ElliptaFluticasone/Vilanterol | 70 | $40,962 |
| XolairOmalizumab | 14 | $27,870 |
| OpzeluraRuxolitinib Phosphate | 11 | $21,714 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $18,969 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $9,280 |
| Arnuity ElliptaFluticasone Furoate | 25 | $7,304 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,496 |
| DuleraMometasone/Formoterol | 14 | $4,862 |
| Azelastine Hcl | 183 | $4,637 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 27 | $2,912 |
| Montelukast Sodium | 287 | $2,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $19,699 | $179,722231 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Cuvitru | $2,087 | $140,77713 claims |
| AstraZenecaFasenra, Breztri Aerosphere, Symbicort | $1,839 | $84,02046 claims |
| Incyte CorporationOpzelura | $298 | $21,71411 claims |
| Boehringer IngelheimSpiriva Respimat | $68 | $6,49612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 426 allergy & immunology providers in California.
Other allergy & immunology in Los Angeles
- Melinda BraskettLos Angeles$223K
- Yat Choi KwongLos Angeles$181K
- Asal NaderiLos Angeles$71K
- Kenneth KimLong Beach$18.5M
- Purvi MehraSan Diego$6.3M
- Bob GengSan Diego$6M
- Alexander GreinerSan Diego$4.8M
- Tonny TanusBakersfield$4.5M
- Raffi TachdjianSanta Monica$4.2M
- Vinay MehtaLaguna Niguel$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.